Context and Aims
Carboxylesterase 1 (CES1) appears to play an important role in the control of the metabolism of triglycerides and cholesterol in adipocytes and other cell types including hepatocytes. Therefore, it is relevant to gain insights into the genetic versus non-genetic mechanisms involved in the control of CES1 mRNA expression. Here, we investigated CES1 mRNA expression level in adipose tissue and its association with measures of adiposity and metabolic function in a population of elderly twins. Furthermore, the heritability of CES1 mRNA expression level in adipose tissue and the effect of CES1 gene duplication were assessed.
A total of 295 monozygotic and dizygotic twin subjects (62–83 years) with (n = 48) or without (n = 247) type 2 diabetes mellitus were enrolled in the study. They were subjected to a standard oral glucose tolerance test and excision of abdominal subcutaneous fat biopsies during the fasting state. Levels of CES1 mRNA and copy number of the gene were assessed by quantitative PCR.
CES1 mRNA expression level in adipose tissue was positively associated with body-mass index (P<0.001), homeostasis model assessment-insulin resistance (P = 0.003) and level of fasting glucose (P = 0.002), insulin (P = 0.006), and triglycerides (P = 0.003). The heritability for the expression of CES1 mRNA in adipose tissue was high. CES1 gene duplication was positively associated with insulin sensitivity (P = 0.05) as well as glucose tolerance (P = 0.03) and negatively associated with homeostasis model assessment-insulin resistance (P = 0.02). Duplication of CES1 was not linked to mRNA level of this gene (P = 0.63).
CES1 mRNA in adipose tissue appears to be under strong genetic control and was associated with measures of metabolic function raising the possibility of a potential role of this enzyme in the development of type 2 diabetes mellitus. Further studies are needed to understand the potential effect of CES1 gene duplication on adipocyte and whole-body metabolic functions.
Citation: Friedrichsen M, Poulsen P, Wojtaszewski J, Hansen PR, Vaag A, et al. (2013) Carboxylesterase 1 Gene Duplication and mRNA Expression in Adipose Tissue Are Linked to Obesity and Metabolic Function. PLoS ONE 8(2): e56861. doi:10.1371/journal.pone.0056861
Editor: Claudia Miele, Consiglio Nazionale delle Ricerche, Italy
Received: October 22, 2012; Accepted: January 14, 2013; Published: February 28, 2013
Copyright: © 2013 Friedrichsen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by grant no. 10-092792/DSF from the Danish Council for Strategic Research, the Programme Commission on Individual and Society (http://en.fi.dk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: MF and HBR are shareholders of Novo Nordisk A/S. PP is an employee Novo Nordisk A/S and shareholder of this company too. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Adipose tissue is the major site for storage of cholesterol and triglycerides in the body ,  The hydrolysis and esterification of lipids in this tissue are closely regulated to maintain a tight balance between lipid release, storage, and trafficking . Disturbance of this balance may lead to insulin resistance, increased plasma levels of triglycerides, and obesity, i.e. components of the metabolic syndrome .
Several enzymes are implicated in the lipid metabolism in human adipose tissue . This includes carboxylesterase 1 (CES1) that seems to play an important role in the hydrolysis of cholesteryl esters and triglycerides . This enzyme uses a hydrolysis mechanism with release of the alcohol substituent from the substrate and formation of a fatty acyl-enzyme intermediate as the first step followed by a second step consisting of reaction of the intermediate with water and release of the acyl group-containing molecule . Apparently, CES1 also possesses cholesterol transferase activity that enables formation of cholesteryl esters in the abundance of free cholesterol . Hence, the enzyme appears to be involved in the de-esterification as well as transesterification of lipids.
A role of carboxylesterases in the lipid metabolism in humans is supported by observations from animal models –. One such study showed that the hydrolysis of triglycerides in adipose tissue was severely decreased in mice with global inactivation of Ces3, recently annotated as Ces1d1, which is the murine ortholog of human CES1 . Moreover, liver specific inactivation of Ces1d1 in mice has been shown to be associated with significantly decreased levels of very low density lipoprotein-triglycerides and -cholesterol in plasma and moderately increased liver triglyceride levels suggesting an important role of hepatic Ces1d1 in the lipid metabolism .
Because CES1 has a potentially significant role in the lipid homeostasis, and its activity has been suggested to be primarily regulated on the transcriptional level , the amount of CES1 mRNA in adipose tissue may serve as an intermediate phenotype providing important information about the mechanisms leading to type 2 diabetes mellitus (T2DM). So far, the expression of CES1 mRNA in T2DM has not been examined. However, it has been suggested that the expression of CES1 mRNA in human adipose tissue is correlated with measures of adiposity and metabolic function including waist circumference, homeostasis model assessment-insulin resistance (HOMA-IR), triglyceride level, and plasma insulin level –. In contrast, findings of a relationship between CES1 mRNA level and other measures of metabolic function such as body-mass index (BMI) and total cholesterol level are inconsistent, possibly reflecting limited statistical power ,  and inclusion of study participants with malignant diseases .
Since CES1 may play an important role in the mechanisms leading to dysregulation of lipid and glucose metabolism and eventually to T2DM , , the heritability of the expression level of CES1 mRNA in adipose tissue is of scientific interest. Yet, this heritability has not been determined. Therefore, the relative contribution of genetic and non-genetic variation to the expression of CES1 mRNA in subcutaneous adipose tissue remains unknown.
A variety of genetic variations may influence CES1 mRNA expression. One such variation is duplication of the gene  that may result in increased production of CES1 mRNA and thus increased CES1 activity albeit the “daughter” copy of the gene has been reported to be transcribed at a lower level than the “mother” copy . Since pseudogenes can affect the mRNA levels of their protein-coding counterparts , another inherited factor that could potentially modulate the level of mRNA of CES1 is carboxylesterase 1 pseudogene 1 (CES1P1), located in the vicinity of CES1 .
In the present study we examined a unique study population of phenotypically well-characterized elderly monozygotic and dizygotic twin subjects (n = 295 individuals) with the aim of providing new information about basal mechanisms underlying T2DM by: 1) assessment of the relationship of CES1 mRNA expression level in subcutaneous adipose tissue with age, gender, measures of glucose and lipid metabolism, and CES1P1 mRNA expression level; 2) determination of the heritability of CES1 mRNA expression in adipose tissue; 3) assessment of the relationship of CES1 copy number with CES1 mRNA expression in adipose tissue and measures of metabolic function in healthy and T2DM subjects.
Materials and Methods
A total of 295 monozygotic (MZ) (n = 125; 48 complete pairs and 29 single twins) and same-sex dizygotic (DZ) (n = 170; 55 complete pairs and 60 single twins) elderly Danish twin subjects (62–83 years) were recruited as previously described , . Glucose tolerance status was determined employing a standard 75-g oral glucose tolerance test (OGTT). The glucose tolerance status was defined according to the WHO 1999 criteria  and ranged from normal glucose tolerance (NGT, n = 169) over impaired glucose tolerance (IGT, n = 78) to overt T2DM (n = 48). Twenty-two subjects had known T2DM and were treated with diet or glucose-lowering medication. An informed consent form was signed by all subjects prior to their inclusion in the study. The signed forms were kept by the principal investigator for documentation purposes. The study with its consent procedure was approved by the Committees on Biomedical Research Ethics for the Capitol Region in Denmark and conducted in adherence with the guidelines of the Helsinki Declaration.
Weight and height as well as waist and hip circumference were measured, and BMI was calculated. Fasting blood samples were analyzed for serum triglyceride and total cholesterol levels using commercial kits from Boerhinger Mannheim (Mannheim, Germany). Insulin resistance was assessed using HOMA-IR: (fasting plasma insulin*fasting plasma glucose/22.5)*0.144 . The composite whole-body insulin sensitivity index (ISI)composite was determined as follows: 10,000/sqrt([fasting glucose*fasting insulin]*[mean glucoseOGTT*mean insulinOGTT]) .
Tissue biopsies. Subcutaneous adipose tissue biopsies were taken from the abdomen in a subgroup of the study population (n = 226). This was done under local anesthesia (lidocaine) using a Bergström needle with suction applied. Specimens were quickly blotted onto filter paper and frozen in liquid nitrogen.
Total RNA was extracted using TRI reagent (Sigma-Aldrich, St. Louis, MO) as described previously . cDNA was synthesized using QuantiTect Reverse Transcription Kit according to the manufacturer’s recommendations (Qiagen, Valencia, CA). We used the standard curve method for quantification of mRNA by TaqMan®-based PCR on an ABI Prism 7900 HT system from Applied Biosystems, now Life Technologies Corporation (Carlsbad, CA). Using reagents also purchased from this company, we determined the mRNA levels of CES1 in 206 individuals (assay identification Hs00275607_m1), while that of CES1P1 only were determined in 159 individuals due to technical issues (assay identification Hs00750233_s1). The mRNA levels were normalized to that of PPIA, cyclophilin A, (part number 4326316E from Life Technologies Corporation) and expressed in arbitrary units. Average Ct values were ~25 for CES1 and PPIA and ~33 for CES1P1. The lower expression of CES1P1 and thus larger variation between the duplicates allowed for fewer duplicates to pass the criteria of a CV% <1%.
Copy Number Determination of CES1
DNA was purified from leukocytes employing Autopure LS® according to the manufacturer’s recommendations (Qiagen GmbH, Hilden, Germany). The copy number determination was performed using real-time PCR followed by comparison of the amounts of gene-specific amplicon to that of a reference gene. For this purpose commercially available fluorescent-labeled reagents were acquired and applied according to the guidelines of the manufacturer (Life Technologies Corporation). These reagents targeted a region in exon 11 of CES1 (assay identification Hs00139541_cn). The gene encoding the ribonuclease P RNA component served as reference gene. Calculation of the gene copy number was accomplished using CopyCaller v 1.0, a program developed by the manufacturer of the assay reagents. In the event of disagreement between duplicate samples, the analysis was repeated. The observed genotype proportions were compared with those expected under Hardy-Weinberg equilibrium using chi-squared test.
All statistical tests were performed using SAS (version 9.2, SAS Institute, Cary, NC). Data were presented as mean±SD. P<0.05 was considered significant. Spearman’s rho was used to evaluate the correlation between continuous variables. Multiple regression analyses allowed for assessment of the effect of CES1 copy number and CES1 mRNA level, while adjusting for twin and zygosity status as well as for additional contributing variables, including age, sex, and BMI . All response variables were log-transformed to avoid skewness of the residuals. This resulted in effects that expressed percentage-wise and not absolute changes in the response variable. Since CES1 mRNA level was expressed in arbitrary units, the association of this variable with others was calculated per doubling from its average. Doubling of the CES1 mRNA level was within 2 SD, which was considered to be biologically plausible. The heritability coefficient, often abbreviated as h2, expresses the proportion of the total variation of a trait attributable to genetic variation. In a twin population the heritability coefficient can be calculated as the degree to which MZ twins are more similar than DZ twins . It was determined as twice the difference of the intra-class correlation coefficients of MZ and DZ twins (h2 = 2[rMZ−rDZ]). A heritability coefficient approaching 0 indicates very limited genetic influence, whereas a heritability coefficient close to 1 indicates that the trait is under strong genetic control.
The clinical characteristics of this population have been described in detail previously .
CES1 and CES1P1 mRNA expression. CES1 mRNA expression level in adipose tissue was significantly affected by age, gender, and BMI (P<0.001 for all variables, Table 1). One year of aging was associated with a decrease in the CES1 mRNA level of 4%, and the expression level in males was 35% lower than in females. Adiposity was associated with a 10% increase in CES1 mRNA level per BMI unit (Table 1 and Figure 1A). Moreover, we found CES1 mRNA level in adipose tissue to be positively associated with HOMA-IR (Table 2 and Figure 1B), where a doubling of this level was associated with a 15% increase in HOMA-IR (P = 0.003). CES1 mRNA level was also positively associated with other measures of metabolic function (Table 2), including cholesterol (P = 0.04), and fasting plasma levels of insulin (P = 0.006), glucose (P = 0.002) and triglycerides (P = 0.003, see also Figure 1C). Conversely, CES1 mRNA level was negatively associated with ISIcomposite (P = 0.005). Finally, there was a positive correlation between the levels of mRNA of CES1 and CES1P1 (Figure 1D). Although CES1 mRNA level was not significantly associated with 120-min OGTT glucose level (Table 2), we found a borderline significant association (P = 0.057) between the levels of OGTT glucose and CES1 mRNA after adjustment for age, sex and BMI (Figure 2). Individuals with IGT and T2DM were combined into one group with impaired glucose regulation. After adjustment for age, sex and BMI the level of CES1 mRNA was 27% higher in the combined group compared with the NGT group (Figure 2).
Correlation of CES1 mRNA level with body-mass index (BMI) (A, n = 204 twin subjects), homeostasis model assessment-insulin resistance (HOMA-IR) (B, n = 203 twin subjects), fasting plasma triglyceride levels (C, n = 205 twin subjects), and CES1P1 mRNA level (D, n = 147 twin subjects), respectively, are shown. Due to technical reasons the level of CES1P1 mRNA could not be determined in a relatively large subpopulation of the twin subjects (for explanation, see ”Materials and Methods“). CES1: Carboxylesterase 1 gene; CES1P1: carboxylesterase 1 pseudogene 1; TG: triglyceride. Spearman’s rho correlation coefficients and the corresponding P-values have been included.
*P<0.05 compared to NGT after adjustment for age, gender, and body-mass index.
Heritability of CES1 and CES1P1 mRNA Expression
The heritability coefficients for the mRNA expression of CES1 and CES1P1 amounted to ~1 and 0.84, respectively. This suggested that genetic effects exhibited a quantitatively predominant influence on the variation of the mRNA expression of these two genes in adipose tissue (Table 3).
CES1 copy number variation. Since the CES1 mRNA expression level in adipose tissue was found to be highly heritable and significantly associated with numerous measures of metabolic function, we evaluated the effect of CES1 duplication, a genetic variation that previously has been suggested to affect the transcript abundance of this gene . Among the subjects in the study population, 6 carried the duplicated allele on both chromosomes, 60 were heterozygotes for this allele, and 138 did not carry the duplicated allele. Based on this observation, the frequency of the duplicated CES1 allele was estimated at 0.18. The genotype proportions conformed to those expected under the condition of Hardy-Weinberg equilibrium (P = 0.86). Due to the small number of subjects having 4 gene copies of CES1, we amalgamated the groups with 3 and 4 copies of CES1 (Table 4). Using this approach we found decreases of 5% and 14% in the fasting level of glucose (P = 0.06) and insulin (P = 0.04), respectively, in the group of subjects with 3 or 4 CES1 gene copies, while there was a 9% increase in ISIcomposite (P = 0.05) in this group compared with individuals harboring 2 copies of the gene (Table 4). Moreover, we found a 19% decrease in of HOMA-IR (P = 0.02) and an 11% decrease in OGTT (P = 0.03) in the group of subjects with 3 or 4 CES1 gene copies. There was no significant association between the gene copy number and CES1 mRNA expression (P = 0.63). Furthermore, CES1 copy number was not associated with measures of adiposity or plasma lipid parameters, including plasma triglyceride and total cholesterol levels. Statistical analysis without amalgamation of the groups with 3 and 4 CES1 copies produced results that were comparable to those obtained with amalgamation. However, a larger effect of CES1 copy number was observed on HOMA-IR (P = 0.002) and level of fasting insulin (P = 0.002) without the amalgamation.
In the present study the mRNA expression level of CES1 in subcutaneous adipose tissue samples derived from monozygotic and dizygotic twins was examined. We report several important findings about the regulation and possible role of CES1 in the lipid and glucose homeostasis. First, we found significant relationships between CES1 mRNA level and age, gender, measures of adiposity, metabolic regulation and CES1P1 mRNA level. Second, a high heritability for the level of mRNA expression of CES1 was detected. Third, CES1 gene copy number was found to be associated with measures of glucose metabolism. Collectively, these findings suggest that CES1 is involved in the pathogenesis of T2DM.
Our study is the first to report that CES1 mRNA level in subcutaneous adipose tissue is negatively correlated with age in a population of elderly subjects, and that CES1 is transcribed at significantly higher levels in women than men. Although a previous small-sized study also found CES1 mRNA expression level in visceral adipose tissue to be inversely associated with age, the association for subcutaneous adipose tissue in this study did not reach statistical significance. However, since the age span in the present study was only 21 years with the youngest subject being 62 years old, it cannot be excluded that age affects CES1 mRNA level in adipose tissue differently in younger individuals. The strong correlations of CES1 mRNA level with BMI, total cholesterol, and fasting plasma glucose and insulin levels observed in the present study are remarkable and may clarify disagreeing findings observed in previous studies , . For example, one study reported lack of association of CES1 mRNA level with BMI , while another study found a strong positive correlation between these two variables . Based upon a large sample our findings support the latter of these two studies. The finding that individuals with dysregulated glucose metabolism, including those with T2DM, displayed higher levels of CES1 mRNA underscores the association of CES1 with glucose metabolism. Our finding of a positive correlation between the expression level of mRNA of CES1P1 and CES1 is interesting and since pseudogenes can affect the levels of mRNA of their protein-coding counterparts , , , it suggests a novel mechanism for regulation of the CES1 mRNA expression in adipose tissue. Previous observations have suggested that the transcripts of a pseudogene and its functional counterpart can compete for the same transacting factors involved in mRNA degradation . Therefore, high levels of transcripts generated from a pseudogene may efficiently protect the transcripts of a functional homolog from degradation, thus increasing its translation. Whether such mechanism is involved in the regulation of CES1 activity is not known. Of importance, a pseudogene has previously been associated with insulin resistance and T2D by another posttransciptional regulation mechanism that involved destabilization of the transcripts generated from a functional homolog .
There are several plausible explanations for the observed associations between the level of CES1 mRNA in subcutaneous adipose tissue and measures of glucose metabolism. Notably, increased CES1-mediated lipolysis in adipose tissue could cause disturbances of the glucose metabolism by elevation of the plasma levels of non-esterified fatty acids that can induce muscle and hepatic insulin resistance ,  Also, cholesterol imbalance in adipocytes seems capable of inducing insulin resistance  and since CES1 is believed to have an important role in regulating the ratio of esterified and non-esterified cholesterol , such regulating role of CES1 could be reflected in the appearance of an association between levels of CES1 mRNA and cholesterol. Alternatively, imbalance in the metabolism of cholesterol or other lipids due to intake of a diet rich in animal fat may lead to an altered blood lipid profile ,  and increments in body fat deposits  that might affect the expression of CES1 mRNA.
In the present study, the heritability of CES1 mRNA expression in subcutaneous adipose tissue was high, exceeding the average heritability of 0.234 for the mRNA expression across genes in subcutaneous adipose tissue previously obtained by analysis of a family cohort . Heritability coefficients have several limitations. For example, they can be inflated by shared pre- as well as post-natal environments . However, even with this limitation the present study suggests the existence of a strong heritable component in the expression of CES1 mRNA in adipose tissue. A strong heritable component in the transcription is characteristic of genes whose transcriptional levels are determined by local regulatory variation , . Hence, the individual differences in the expression level of CES1 mRNA observed in the present study may to large extent reflect variation within this gene or in genes in its vicinity.
A genetic variation potentially conferring individual differences in the expression of CES1 is duplication of the gene , . Previously, the frequency of the duplicated allele of CES1 was determined at 0.20 among voluntary blood donors in Denmark (Rasmussen et al., unpublished results). Although slightly lower, the observed frequency of this allele in the present study, based upon related as well as unrelated subjects, was in accordance with this value. Apparently, the transcription in adipose tissue by genotypes with 3 or 4 copies of CES1 was comparable with that of genotypes composed of 2 copies of the gene. Probably, this reflects that the “daughter” copy, often designated CES1A2, is transcribed at a low level and therefore does not contribute substantially to the total amounts of CES1 transcripts. This is in agreement with findings obtained by analysis of human livers , while the expression of CES1A2 has been found to be high in several cell lines . In addition to gene duplication, variation in the promoter region of a gene can affect the amounts of transcripts produced. There are several promoter variants in CES1 with a presumed effect on the transcription of this gene , . However, these effects remain to be confirmed.
The copy number of the gene encoding CES1, including “mother” as well as “daughter” copies, was associated with several measures of glucose metabolism. More specifically, presence of 2 copies of CES1 appeared to predispose to a negative phenotype and influence the susceptibility to T2DM suggesting that the present study identified a novel genetic factor affecting the risk of developing this disorder. In this regard, the lack of association between CES1 gene copy number variation and mRNA level in adipose tissue is surprising, when this genetic variation is proposed to have effects on glucose and lipid metabolisms. One explanation for this apparent discrepancy may be that the duplicated version of CES1 is in linkage disequilibrium with a gene variant that affects glucose metabolism indirectly or directly without increasing the expression of CES1 mRNA. An alternative possibility is that CES1 activity in adipose tissue is predominantly regulated by posttranscriptional mechanisms including pseudogene-mediated transcript protection, a mechanism that appears to play a role in the regulation of several other genes , , . This is an interesting possibility since the haplotype harboring the duplicated allele lacks CES1P1, while this pseudogene is present on the haplotype with the unduplicated allele . Therefore, the latter of these two haplotypes has a potential for generation of CES1P1 transcripts.
Pseudogenes may act through different mechanisms , , . Notably, antisense transcripts generated from these genetic elements have been implicated in the translational silencing of their functional homologs , . It is possible that pseudogen-mediated posttranscriptional regulation is involved in determining CES1 activity and that this explains some of the findings from the present study. Regulation of the activity of CES1 may, however, be even more complex as it also seems to include regulatory control on the protein level by endogenous small molecules, such as cholesterol-like molecules . Therefore, CES1 activity may not be correlated with level of CES1 mRNA and copy number status of CES1.
Various aspects of the role of CES1 in lipid metabolism remain to be clarified including the importance of CES1-mediated lipolysis in adipose tissue relative to that in the liver. A recent study raised doubts about the importance of CES1 in the hydrolysis of triglycerides in adipose tissue and suggested that other lipases were more important in this respect , while another study reported a major role of CES1 in the trafficking of lipids and lipid metabolism in hepatocytes . Whether CES1 is more important to the triglyceride metabolism in the liver than adipose tissue of humans is not yet known. However, using mice with global knock-out of Ces1d1, the murine ortholog of the human CES1, a recent study attributed most of the reduction in plasma triglycerides resulting from this gene knock-out to the absence of hepatic activity of Ces1d1 . If CES1 has a role in the metabolic regulation in the liver that is comparable to its murine ortholog, this would explain our finding that CES1 gene copy number was associated with insulin resistance in the fasting state (HOMA-IR), which is thought to be primarily hepatically determined .
The positive association between CES1 gene copy number and ISIcomposite suggests that variations in this gene impacts on the peripheral insulin sensitivity , possibly affecting glucose metabolism or insulin sensitivity in skeletal muscle. Although it is known that insulin sensitivity is under strong genetic control , , very few genetic variations affecting insulin sensitivity in the liver or skeletal muscle have been identified so far. Our results, suggest that copy number variation of CES1 could be involved in mediating such effects. Finally, besides the association with ISIcomposite, CES1 copy number was associated with glucose tolerance, a positive association that might reflect an effect on beta cell function and insulin secretion.
In conclusion, the present study links the expression level of CES1 mRNA with risk factors for T2DM and suggests that copy number variation of CES1 influences measures of glucose metabolism, perhaps contributing to the genetic susceptibility to T2DM. This knowledge may be valuable for future research aimed at understanding the genetic architecture predisposing for T2DM.
We thank the study participants. Additionally, the technical assistance of Marianne Modest is gratefully acknowledged.
Conceived and designed the experiments: MF AV HBR PP JW PRH. Performed the experiments: MF AV HBR. Analyzed the data: MF HBR. Contributed reagents/materials/analysis tools: PP AV MF. Wrote the paper: MF PP JW PRH AV HBR.
- 1. Havel RJ (1972) Caloric homeostasis and disorders of fuel transport. N Engl J Med 287: 1186–1192 doi:10.1056/NEJM197212072872307.
- 2. Yu BL, Zhao SP, Hu JR (2010) Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity. Obes Rev 11: 560–567 doi:10.1111/j.1467-789X.2009.00699.x.
- 3. Watt MJ, Steinberg GR (2008) Regulation and function of triacylglycerol lipases in cellular metabolism. Biochem J 414: 313–325 doi:10.1042/BJ20080305.
- 4. Arner P, Langin D (2007) The role of neutral lipases in human adipose tissue lipolysis. Curr Opin Lipidol 18: 246–250 doi:10.1097/MOL.0b013e32811e16fb.
- 5. Quiroga AD, Lehner R (2011) Role of endoplasmic reticulum neutral lipid hydrolases. Trends Endocrinol Metab 22: 218–225 doi:10.1016/j.tem.2011.03.003.
- 6. Satoh T, Hosokawa M (2006) Structure, function and regulation of carboxylesterases. Chemico-Biological Interactions 162: 195–211 doi:10.1016/j.cbi.2006.07.001.
- 7. Becker A, Böttcher A, Lackner KJ, Fehringer P, Notka F, et al. (1994) Purification, cloning, and expression of a human enzyme with acyl coenzyme A: cholesterol acyltransferase activity, which is identical to liver carboxylesterase. Arterioscler Thromb 14: 1346–1355. doi: 10.1161/01.atv.14.8.1346
- 8. Wei E, Ben Ali Y, Lyon J, Wang H, Nelson R, et al. (2010) Loss of TGH/Ces3 in mice decreases blood lipids, improves glucose tolerance, and increases energy expenditure. Cell Metab 11: 183–193 doi:10.1016/j.cmet.2010.02.005.
- 9. Lian J, Wei E, Wang SP, Quiroga AD, Li L, et al.. (2012) Liver specific inactivation of carboxylesterase 3/Triacylglycerol hydrolase decreases blood lipids without causing severe steatosis. Hepatology (Baltimore, Md). doi:10.1002/hep.25881.
- 10. Quiroga AD, Li L, Trötzmüller M, Nelson R, Proctor SD, et al.. (2012) Deficiency of carboxylesterase 1/esterase-x in mice results in obesity, hepatic steatosis and hyperlipidemia. Hepatology (Baltimore, Md). doi:10.1002/hep.25961.
- 11. Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJY, et al. (2009) Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 77: 238–247 doi:10.1016/j.bcp.2008.10.005.
- 12. Jernås M, Olsson B, Arner P, Jacobson P, Sjöström L, et al. (2009) Regulation of carboxylesterase 1 (CES1) in human adipose tissue. Biochem Biophys Res Commun 383: 63–67 doi:10.1016/j.bbrc.2009.03.120.
- 13. Marrades MP, González-Muniesa P, Martínez JA, Moreno-Aliaga MJ (2010) A dysregulation in CES1, APOE and other lipid metabolism-related genes is associated to cardiovascular risk factors linked to obesity. Obes Facts 3: 312–318 doi:10.1159/000321451.
- 14. Nagashima S, Yagyu H, Takahashi N, Kurashina T, Takahashi M, et al. (2011) Depot-specific expression of lipolytic genes in human adipose tissues–association among CES1 expression, triglyceride lipase activity and adiposity. J Atheroscler Thromb 18: 190–199. doi: 10.5551/jat.6478
- 15. Fukami T, Nakajima M, Maruichi T, Takahashi S, Takamiya M, et al. (2008) Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics 18: 911–920 doi:10.1097/FPC.0b013e32830b0c5e.
- 16. Tanimoto K, Kaneyasu M, Shimokuni T, Hiyama K, Nishiyama M (2007) Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro. Pharmacogenet Genomics 17: 1–10 doi:10.1097/01.fpc.0000230110.18957.50.
- 17. Pink RC, Wicks K, Caley DP, Punch EK, Jacobs L, et al. (2011) Pseudogenes: pseudo-functional or key regulators in health and disease? RNA 17: 792–798 doi:10.1261/rna.2658311.
- 18. Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, et al. (2010) Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J 10: 524–536 doi:10.1038/tpj.2010.5.
- 19. Poulsen P, Vaag A, Beck-Nielsen H (1999) Does zygosity influence the metabolic profile of twins? A population based cross sectional study. BMJ 319: 151–154. doi: 10.1136/bmj.319.7203.151
- 20. Poulsen P, Grunnet LG, Pilgaard K, Storgaard H, Alibegovic A, et al. (2009) Increased risk of type 2 diabetes in elderly twins. Diabetes 58: 1350–1355 doi:10.2337/db08-1714.
- 21. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, et al. (2000) The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23: 1108–1112. doi: 10.2337/diacare.23.8.1108
- 22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419. doi: 10.1007/bf00280883
- 23. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462–1470. doi: 10.2337/diacare.22.9.1462
- 24. Palsgaard J, Brøns C, Friedrichsen M, Dominguez H, Jensen M, et al. (2009) Gene expression in skeletal muscle biopsies from people with type 2 diabetes and relatives: differential regulation of insulin signaling pathways. PLoS ONE 4: e6575 doi:10.1371/journal.pone.0006575.
- 25. Friedrichsen M, Poulsen P, Richter EA, Hansen BF, Birk JB, et al. (2010) Differential aetiology and impact of phosphoinositide 3-kinase (PI3K) and Akt signalling in skeletal muscle on in vivo insulin action. Diabetologia 53: 1998–2007 doi:10.1007/s00125-010-1795–8.
- 26. Wood AC, Neale MC (2010) Twin studies and their implications for molecular genetic studies: endophenotypes integrate quantitative and molecular genetics in ADHD research. J Am Acad Child Adolesc Psychiatry 49: 874–883 doi:10.1016/j.jaac.2010.06.006.
- 27. Piehler AP, Hellum M, Wenzel JJ, Kaminski E, Haug KBF, et al. (2008) The human ABC transporter pseudogene family: Evidence for transcription and gene-pseudogene interference. BMC Genomics 9: 165 doi:10.1186/1471-2164-9-165.
- 28. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515–524 doi:10.1101/gad.1399806.
- 29. Chiefari E, Iiritano S, Paonessa F, Le Pera I, Arcidiacono B, et al (2010) Pseudogene-mediated posttranscriptional silencing of HMGA1 can result in insulin resistance and type 2 diabetes. Nat Commun 1: 40 doi:10.1038/ncomms1040.
- 30. Boden G (2003) Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 111: 121–124 doi:10.1055/s-2003-39781.
- 31. Nakamura S, Takamura T, Matsuzawa-Nagata N, Takayama H, Misu H, et al. (2009) Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem 284: 14809–14818 doi:10.1074/jbc.M901488200.
- 32. Bencharit S, Edwards CC, Morton CL, Howard-Williams EL, Kuhn P, et al. (2006) Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. J Mol Biol 363: 201–214 doi:10.1016/j.jmb.2006.08.025.
- 33. Lee HY, Woo J, Chen ZY, Leung SF, Peng XH (2000) Serum fatty acid, lipid profile and dietary intake of Hong Kong Chinese omnivores and vegetarians. Eur J Clin Nutr 54: 768–773. doi: 10.1038/sj.ejcn.1601089
- 34. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM (2010) Saturated fatty acids and risk of coronary heart disease: modulation by replacement nutrients. Curr Atheroscler Rep 12: 384–390 doi:10.1007/s11883-010-0131-6.
- 35. Field AE, Willett WC, Lissner L, Colditz GA (2007) Dietary fat and weight gain among women in the Nurses’ Health Study. Obesity (Silver Spring) 15: 967–976 doi:10.1038/oby.2007.616.
- 36. Price AL, Helgason A, Thorleifsson G, McCarroll SA, Kong A, et al. (2011) Single-tissue and cross-tissue heritability of gene expression via identity-by-descent in related or unrelated individuals. PLoS Genet 7: e1001317 doi:10.1371/journal.pgen.1001317.
- 37. Vaag A, Poulsen P (2007) Twins in metabolic and diabetes research: what do they tell us? Curr Opin Clin Nutr Metab Care 10: 591–596 doi:10.1097/MCO.0b013e3282ab9ea6.
- 38. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, et al. (2008) Genetics of gene expression and its effect on disease. Nature 452: 423–428 doi:10.1038/nature06758.
- 39. Petretto E, Mangion J, Dickens NJ, Cook SA, Kumaran MK, et al. (2006) Heritability and tissue specificity of expression quantitative trait loci. PLoS Genet 2: e172 doi:10.1371/journal.pgen.0020172.
- 40. Bruxel EM, Salatino-Oliveira A, Genro JP, Zeni CP, Polanczyk GV, et al.. (2012) Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J. doi:10.1038/tpj.2012.25.
- 41. Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, et al. (2005) A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res 28: 719–725 doi:10.1291/hypres.28.719.
- 42. Blais DR, Lyn RK, Joyce MA, Rouleau Y, Steenbergen R, et al. (2010) Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication. J Biol Chem 285: 25602–25612 doi:10.1074/jbc.M110.135483.
- 43. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27: 1487–1495. doi: 10.2337/diacare.27.6.1487
- 44. Mayer EJ, Newman B, Austin MA, Zhang D, Quesenberry CP Jr, et al. (1996) Genetic and environmental influences on insulin levels and the insulin resistance syndrome: an analysis of women twins. Am J Epidemiol 143: 323–332. doi: 10.1093/oxfordjournals.aje.a008746
- 45. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, et al. (2005) Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 54: 275–283. doi: 10.2337/diabetes.54.1.275